{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:58:05Z","timestamp":1720461485007},"reference-count":23,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2023,3,31]]},"DOI":"10.1536\/ihj.22-563","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T22:25:37Z","timestamp":1680215137000},"page":"316-320","source":"Crossref","is-referenced-by-count":7,"title":["Dramatically Improved Severe Pulmonary Arterial Hypertension Caused by Qing-Dai (Chinese Herbal Drug) for Ulcerative Colitis"],"prefix":"10.1536","volume":"64","author":[{"given":"Kana","family":"Kubota","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University"},{"name":"Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ishiyama","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ueno","sequence":"additional","affiliation":[{"name":"Ueno Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Suzuki H, Kaneko T, Mizokami Y, <i>et al<\/i>. Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J Gastroenterol 2013; 19: 2718-22.","DOI":"10.3748\/wjg.v19.i17.2718"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Naganuma M, Sugimoto S, Mitsuyama K, <i>et al<\/i>. Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis. Gastroenterology 2018; 154: 935-47.","DOI":"10.1053\/j.gastro.2017.11.024"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Sugimoto S, Naganuma M, Kiyohara H, <i>et al<\/i>. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion 2016; 93: 193-201.","DOI":"10.1159\/000444217"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nishio M, Hirooka K, Doi Y. Chinese herbal drug natural indigo may cause pulmonary artery hypertension. Eur Heart J 2016; 37: 1992.","DOI":"10.1093\/eurheartj\/ehw090"},{"key":"5","unstructured":"5. Notification for Ensuring the Safety of Health Foods. Ministry of Health, Labour and Welfare. Available at: http:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/shokuhin\/hokenkinou\/houreituuti.html. Accessed February, 2023 (Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Naganuma M, Sugimoto S, Suzuki H, <i>et al<\/i>. Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J Gastroenterol 2019; 54: 891-6.","DOI":"10.1007\/s00535-019-01591-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Simonneau G, Montani D, Celermajer DS, <i>et al<\/i>. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.","DOI":"10.1183\/13993003.01913-2018"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Misumi K, Ogo T, Ueda J, <i>et al<\/i>. Development of pulmonary arterial hypertension in a patient treated with Qing-Dai (Chinese herbal medicine). Intern Med 2019; 58: 395-9.","DOI":"10.2169\/internalmedicine.1523-18"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sato K, Ohira H, Horinouchi T, <i>et al<\/i>. Chinese herbal medicine Qing-Dai-induced pulmonary arterial hypertension in a patient with ulcerative colitis: a case report and experimental investigation. Respir Med Case Rep 2019; 26: 265-9.","DOI":"10.1016\/j.rmcr.2019.02.007"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002; 8: 158-61.","DOI":"10.3748\/wjg.v8.i1.158"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ouyang Q, Hu PJ, Qian JM, <i>et al<\/i>. Chinese cooperative group for the study on IBD, Chinese society of gastroenterology. Consensus on the management of inflammatory bowel disease in China in 2007. J Dig Dis 2008; 9: 52-62.","DOI":"10.1111\/j.1443-9573.2007.00320.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nishio M, Hirooka K, Doi Y. Pulmonary arterial hypertension associated with the Chinese herb indigo Naturalis for ulcerative colitis: it may be reversible. Gastroenterology 2018; 155: 577-8.","DOI":"10.1053\/j.gastro.2018.04.038"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kawai S, Iijima H, Shinzaki S, <i>et al<\/i>. Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation. J Gastroenterol 2017; 52: 904-19.","DOI":"10.1007\/s00535-016-1292-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cheng X, Alborzinia H, Merz KH, <i>et al<\/i>. Indirubin derivatives modulate TGF\u03b2\/BMP signaling at different levels and trigger ubiquitin-mediated depletion of nonactivated R-Smads. Chem Biol 2012; 19: 1423-36.","DOI":"10.1016\/j.chembiol.2012.09.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. International PPH Consortium, Lane KB, Machado RD, <i>et al<\/i>. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-4.","DOI":"10.1038\/79226"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Machado RD, Aldred MA, James V, <i>et al<\/i>. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27: 121-32.","DOI":"10.1002\/humu.20285"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hoessel R, Leclerc S, Endicott JA, <i>et al<\/i>. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1: 60-7.","DOI":"10.1038\/9035"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Montani D, Bergot E, G\u00fcnther S, <i>et al<\/i>. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-37.","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Seegobin K, Babbar A, Ferreira J, Lyons B, Cury J, Seeram V. A case of worsening pulmonary arterial hypertension and pleural effusions by Bosutinib after prior treatment with dasatinib. Pulm Circ 2017; 7: 808-12.","DOI":"10.1177\/2045893217733444"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Quilot FM, Georges M, Favrolt N, <i>et al<\/i>. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 2016; 47: 676-9.","DOI":"10.1183\/13993003.01110-2015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Alkhatib Y, Albashaireh D, Al-Aqtash T, Awdish R. The role of tyrosine kinase inhibitor &quot;Lapatinib&quot; in pulmonary hypertension. Pulm Pharmacol Ther 2016; 37: 81-4.","DOI":"10.1016\/j.pupt.2016.03.002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Orihara Y, Asakura M, Hida N, <i>et al<\/i>. Effect of oral Qing-Dai medication on pulmonary arterial pressure levels in patients with ulcerative colitis. Circ J 2020; 84: 1339-45.","DOI":"10.1253\/circj.CJ-19-1112"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Adachi S, Nakano Y, Kondo T. Risk of pulmonary arterial hypertension during Qing-Dai use for the treatment of ulcerative colitis. Circ J 2020; 84: 1235-6.","DOI":"10.1253\/circj.CJ-20-0621"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/2\/64_22-563\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:06:19Z","timestamp":1715317579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/2\/64_22-563\/_article"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.22-563","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"article-number":"22-563"}}